Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ROXI-APEX: REGN7508 vs Apixaban/Enoxaparin for VTE Prophylaxis After Knee Replacement
NCT07015905Phase 3Recruiting
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jun 2025
- Primary completion
- Feb 2027
- Modality
- Monoclonal Antibodies
- Countries
- 8
01
Overview
A Phase 3 trial of REGN7508 in venous thromboembolism (VTE), sponsored by Regeneron Pharmaceuticals. Started Jun 2025; status: recruiting.
02
Drugs
REGN7508
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT07015905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07015905.